

the Federal Advisory Committee Act (FACA), section 10(d) of 5 U.S.C., Appendix 2, implementing regulations, and procurement regulations, 41 CFR 101-6.1023 and 48 CFR 315.604(d). The discussions at this meeting of contract proposals submitted in response to the above-referenced RFP are likely to reveal proprietary information and personal information concerning individuals associated with the proposals. Such information is exempt from disclosure under the above-cited FACA provision and procurement rules that protect the free exchange of candid views and facilitate Department and Committee operations.

Name of TRC: The Agency for Healthcare Research and Quality—"Communications Support".

Date: August 18, 2003 (Closed to the public).

Place: Agency for Healthcare Research & Quality, 540 Gaither Road, Conference Room 1, Rockville, Maryland 20850.

Contact Person: Anyone wishing to obtain information regarding this meeting should contact Kevin Murray, Office of Communications and Knowledge Transfer, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, Maryland, 20850, 301-427-1853.

Dated: July 23, 2003

Carolyn M. Clancy,
Director.

[FR Doc. 03-19539 Filed 7-30-03; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Evaluation of Web-Based HIV Risk Behavior Surveillance Among Men Who Have Sex With Men, Program Announcement Number 03095

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Evaluation of Web-Based HIV Risk Behavior Surveillance Among Men Who Have Sex With Men, Program Announcement Number 03095.

Times and Dates: 7 p.m.-8 p.m., August 20, 2003 (Open), 8 a.m.-08:30 a.m., August 21, 2003 (Open), 8:30 a.m.-5 p.m., August 21, 2003 (Closed).

Place: The Westin Atlanta Airport Hotel, 4736 Best Road, Atlanta, GA 30337, Telephone 404.762.7676.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement Number 03095.

Contact Person for More Information: Beth Wolfe, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, 1600 Clifton Road, NE, MS-E07, Atlanta, GA 30333, Telephone 404.639.8531.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: July 23, 2003.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 03-19480 Filed 7-30-03; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[Program Announcement No. ACYF/HS-2003-15]

Fiscal Year 2003 Discretionary Announcement for Head Start Partnerships With Historically Black Colleges and Universities; Availability of Funds and Requests for Applications; Corrections

AGENCY: Administration for Children and Families (ACF), HHS.

ACTION: Correction Notice for Head Start Historically Black Colleges and Universities Program Announcement No. ACYF/HHS-2003-15

SUMMARY: There is a correction notice for the Head Start Historically Black Colleges and Universities funding notice FR Doc 03-18165 that was published on July 21, 2003 (68 FR 43113). The document contained incorrect due dates for receipt of applications.

FOR FURTHER INFORMATION CONTACT: The Head Start Discretionary Grant Support Team (1-800-351-2293) is available to answer questions concerning application requirements and to refer you to the appropriate contact person in

ACYF for programmatic questions. You may e-mail your questions to : HSB@esilsg.org. When contacting ACYF directly with programmatic questions please send to William F. Wilson, Grants Officer 330 C Street, SW., Washington, DC 20447, (202) 205-8913, wwilson@acf.hhs.gov. In order necessary, if you plan to submit an application you are requested to send a post card or call with the following information: the name, address, telephone and fax numbers, and e-mail addresses of the college/university at least four weeks prior to the submission deadline date to: ACYF Operations Center, Historically Black Colleges and Universities, 1150 Connecticut Avenue, NW., Suite 1100, Washington DC 20036, Telephone: 1-800-351-2293, e-mail: HSB@esilsg.org. An application kit including the necessary application forms and appendices can be obtained by contacting the above address, and/or visiting the ACYF Web site at: <http://www.acf.hhs.gov/programs/hsb/grant/fundingopportunities/fundopport.htm>.

Correction: In the **Federal Register** of July 21, 2003 in FR Doc 03-18165, on page 43119 the due date for receipt of applications is August 20, 2003. Please use this deadline date for submissions of applications for funding opportunities available for the FY '03 Head Start Historically Black Colleges and Universities program.

Dated: July 25, 2003.

Joan E. Ohl,

Commissioner, Administration on Children, Youth and Families.

[FR Doc. 03-19456 Filed 7-23-03; 8:45 am]

BILLING CODE 4184-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2002E-0339]

Determination of Regulatory Review Period for Purposes of Patent Extension; BENICAR

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for BENICAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.